Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Other Non-current Assets
Long-term assets not reported separately.
Emergent BioSolutions Inc.NYSE: EBS
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets broadly unchanged from a year ago
Other non-current assets stood at $13M at the end of Q1 FY2026, down 0.8% from a year earlier and down 8.5% from the prior quarter. Over 3 fiscal years it compounded at -56.4% a year.
Context
- Other non-current assets amounted to 1.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -0.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 14.2M USD
- Year-over-year change
- -24.9%
- 4-year CAGR
- -17.0%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.2M | -24.9% |
| FY2024 | 2024-12-31 | 18.9M | -89.4% |
| FY2023 | 2023-12-31 | 178.1M | +3.6% |
| FY2022 | 2022-12-31 | 171.9M | +474.9% |
| FY2021 | 2021-12-31 | 29.9M | — |
Other Non-current Assets vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -0.8% is the 6th highest of 10, against a peer median of +55.5%.
- Other non-current assets amounts to 1.0% of total assets for EBS, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $16.5M USD | +56.7% | +82.5% | 3.1% | |
| Mar 2026 | $16.13M USD | +176.5% | +82.3% | 3.1% | |
| Mar 2026 | $13.91M USD | +70.2% | +30.9% | 2.6% | |
| Mar 2026 | $13M USD | -0.8% | -56.4% | 1.0% | |
| Mar 2026 | CA$2.51M CAD | -36.0% | -19.2% | 0.2% | |
| Mar 2026 | $2.36M USD | +55.5% | +43.9% | 0.5% | |
| Mar 2026 | $1.72M USD | +173.4% | +87.8% | 0.7% | |
| Mar 2026 | $635K USD | -47.7% | -53.7% | 0.4% | |
| Mar 2026 | $482K USD | -64.4% | -66.4% | 0.1% | |
| Mar 2026 | $203.36K USD | -10.2% | -8.6% | 0.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding EBS) | — | +55.5% | +30.9% | 0.5% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 278.9M | 159.2M | 191M | 154.5M | 84.2M |
| Inventory | 344.5M | 350.7M | 328.9M | 311.7M | 343.4M |
| Other Current Assets | 70.2M | 57.9M | 47.9M | 33M | 29.5M |
| Total Current Assets | 1.27B | 1.21B | 679.5M | 598.7M | 662.5M |
| Property, Plant & Equipment (Net) | 828.4M | 837M | 399M | 270.6M | 205.4M |
| Goodwill | 224.9M | 218.2M | 0 | 0 | 0 |
| Intangible Assets | 604.6M | 728.8M | 566.6M | 501.5M | 436.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 29.9M | 171.9M | 178.1M | 18.9M | 14.2M |
| Total Non-current Assets | 1.69B | 1.96B | 1.14B | 791M | 656.1M |
| Total Assets | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B |
| Account Payables | 128.9M | 103.5M | 112.2M | 60.9M | 55.6M |
| Short-term Debt | 37.4M | 963.1M | 413.7M | 2.7M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.7M | 26.4M | 0 | 0 | 0 |
| Other Current Liabilities | 107.3M | 48.6M | 106.8M | 81.1M | 76.6M |
| Total Current Liabilities | 374M | 1.23B | 651.3M | 162.4M | 132.2M |
| Long-term Debt | 809.4M | 448.5M | 446.5M | 663.7M | 572.1M |
| Deferred Tax Liabilities | 93.3M | 59.7M | 47.2M | 41.7M | 37.8M |
| Deferred Revenue (Non-current) | 4.7M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 40.6M | 26.7M | 28.9M | 29.4M | 53.9M |
| Total Non-current Liabilities | 972.2M | 549.7M | 522.6M | 744.5M | 663.8M |
| Total Liabilities | 1.35B | 1.78B | 1.17B | 906.9M | 796M |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 950.3M | 738.7M | (21.8M) | (212.4M) | (159.8M) |
| Accumulated OCI | (16.1M) | 3.1M | (5.7M) | (5.2M) | (7.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.61B | 1.39B | 649.3M | 482.8M | 522.6M |
| Total Debt | 871M | 1.43B | 860.2M | 676.1M | 572.1M |
| Net Debt | 294.7M | 783.8M | 748.5M | 576.6M | 366.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.